Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to 0.85.

  • Altimmune's Equity Ratio fell 580.76% to 0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85, marking a year-over-year decrease of 580.76%. This contributed to the annual value of 0.89 for FY2024, which is 378.5% down from last year.
  • Latest data reveals that Altimmune reported Equity Ratio of 0.85 as of Q3 2025, which was down 580.76% from 0.85 recorded in Q2 2025.
  • Altimmune's Equity Ratio's 5-year high stood at 0.94 during Q2 2021, with a 5-year trough of 0.85 in Q2 2025.
  • In the last 5 years, Altimmune's Equity Ratio had a median value of 0.9 in 2023 and averaged 0.9.
  • Its Equity Ratio has fluctuated over the past 5 years, first surged by 2093.92% in 2021, then crashed by 580.76% in 2025.
  • Over the past 5 years, Altimmune's Equity Ratio (Quarter) stood at 0.91 in 2021, then fell by 1.58% to 0.9 in 2022, then rose by 2.91% to 0.92 in 2023, then dropped by 3.78% to 0.89 in 2024, then dropped by 4.17% to 0.85 in 2025.
  • Its Equity Ratio stands at 0.85 for Q3 2025, versus 0.85 for Q2 2025 and 0.9 for Q1 2025.